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Background
According to a nationwide molecular epidemiology study,
A/E recombinant form accounted for 15% prevalence in
China. Thus, the preliminary object for HIV vaccine devel-
opment in China is to obtain an efficacious vaccine target-
ing this clade. AE2F strain was isolated during the very
early prevalence studies and, therefore, it might be consid-
ered as ancestor-like sequence in China. Here we designed
a DNA vaccine and a recombinant Tiantan vaccinia vac-
cine (rTTV) encoding gp140 gene derived from HIV-
1ae2f(AE) strain, and evaluated their expression in vitro
and the immunogenicity of the DNA vaccine in vivo.
Methods
Humanized gene sequence encoding gp140 of HIV-1
AE2F was synthesized and cloned into the expression vec-
tor to generate DNA vaccine. The same sequence was
cloned into shuttle plasmid and used to construct recom-
binant vaccinia virus by homologous recombination.
Expression of the above two vaccines were determined
with Western blotting assay. Mice were immunized by
DNA vaccine and splenocytes were collected for IFN-γ
based Elispot assay. A set of more than 200 peptides span-
ning the gp160 of A/E clade was used to formulate 4 pep-
tide pools as stimulus.
Results
Western blotting demonstrated that the DNA vaccine and
recombinant vaccinia vaccine can express HIV immuno-
gen gp140 well in vitro. In vivo, the mice immunized with
the DNA vaccine had a Env-specific T-cell immune
response (2433 ± 1437 SFCs/106 splenocytes) compared
to mock mice. The magnitude of T cell response stimu-
lated with first peptide pool (Env1, 1625 ± 1048 SFCs/106
splenocytes) was significantly higher than those with the
other three peptide pool (Env2, 71 ± 37 SFCs/106 spleno-
cytes; Env3, 290 ± 213 SFCs/106 splenocytes; Env4, 447 ±
269 SFCs/106 splenocytes).
Conclusion
The two vaccines can express corresponding immunogen
well and the DNA vaccine can elicit strong T cell response
in mice. Based on the Elispot analysis, the predominant T
cell epitope of A/E clade Env might be among the first two
hundred amino acids.
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